氟康唑、酮康唑、伊曲康唑和伏立康唑上市后不良反应信号的挖掘与分析(4)
[ 5 ] WEISS-SMITH S,DESHPANDE G,CHUNG S,et al. The FDA drug safety surveillance program:adverse event reporting trends[J]. Arch Intern Med,2011,171(6):591-593.[ 6 ] FUJIMOTO M,HOSOMI K,TAKADA M. Statin-associated lower urinary tract symptoms:data mining of the public version of the FDA adverse event reporting system,FAERS[J]. Int J Clin Pharmacol Ther,2014,52(4):259- 266.
[ 7 ] 汤榕 ......
您现在查看是摘要页,全文长 3428 字符。